StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Juno Therapeutics (JUNO) Worth $110/Share in Takeover - Citi
January 17, 2018 8:09 AM
Citi analyst Robyn Karnauskas weighed in on Juno Therapeutics (NASDAQ: JUNO) amid reports that Celgene (NASDAQ: CELG) is in talks ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Rumors
Next Articles
Juno Therapeutics (JUNO) Surges on Takeover Report as Wall Street Debates Potential Deal Valuation
January 17, 2018 12:31 PM
Juno Therapeutics (JUNO) Worth $88+ in Takeover - Leerink
January 17, 2018 8:41 AM
Juno Therapeutics (JUNO): Raising PT To $63 On Possible Acquisition - Wells Fargo
January 17, 2018 7:16 AM
Juno Therapeutics (JUNO) Acquisition Rumor Could Boost Other CAR T Stocks - Suntrust
January 17, 2018 7:07 AM
Juno Therapeutics (JUNO) call put ratio 2.25 calls to 1 put into WSJ report that it is in talks to be acquired by Celgene (CELG)
January 17, 2018 6:08 AM
Options expected to have increasing volume: JUNO GS AXP MS F
January 17, 2018 5:13 AM
After-Hours Stock Movers 01/16: (JUNO) (NEWA) (VRS) Higher; (ATEN) (HIVE) (OBLN) Lower (more...)
January 16, 2018 6:12 PM
bluebird bio (BLUE) Gains on Juno Headlines
January 16, 2018 4:47 PM
Celgene (CELG) is in Talks to Buy Juno Therapeutics (JUNO) - WSJ
January 16, 2018 4:42 PM
